JP2014530000A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014530000A5 JP2014530000A5 JP2014531334A JP2014531334A JP2014530000A5 JP 2014530000 A5 JP2014530000 A5 JP 2014530000A5 JP 2014531334 A JP2014531334 A JP 2014531334A JP 2014531334 A JP2014531334 A JP 2014531334A JP 2014530000 A5 JP2014530000 A5 JP 2014530000A5
- Authority
- JP
- Japan
- Prior art keywords
- vector
- hiv
- gag
- pol
- pol protein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11306222 | 2011-09-26 | ||
| EP11306222 | 2011-09-26 | ||
| PCT/IB2012/002363 WO2013046034A2 (en) | 2011-09-26 | 2012-09-25 | Use of non-subtype b gag proteins for lentiviral packaging |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016178074A Division JP2017018132A (ja) | 2011-09-26 | 2016-09-12 | レンチウイルスパッケージ化のための非サブタイプｂのｇａｇタンパク質の使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014530000A JP2014530000A (ja) | 2014-11-17 |
| JP2014530000A5 true JP2014530000A5 (enExample) | 2014-12-25 |
| JP6495653B2 JP6495653B2 (ja) | 2019-04-03 |
Family
ID=47522726
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014531334A Active JP6495653B2 (ja) | 2011-09-26 | 2012-09-25 | レンチウイルスパッケージ化のための非サブタイプｂのｇａｇタンパク質の使用 |
| JP2016178074A Pending JP2017018132A (ja) | 2011-09-26 | 2016-09-12 | レンチウイルスパッケージ化のための非サブタイプｂのｇａｇタンパク質の使用 |
| JP2018135840A Pending JP2018183165A (ja) | 2011-09-26 | 2018-07-19 | レンチウイルスパッケージ化のための非サブタイプｂのｇａｇタンパク質の使用 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016178074A Pending JP2017018132A (ja) | 2011-09-26 | 2016-09-12 | レンチウイルスパッケージ化のための非サブタイプｂのｇａｇタンパク質の使用 |
| JP2018135840A Pending JP2018183165A (ja) | 2011-09-26 | 2018-07-19 | レンチウイルスパッケージ化のための非サブタイプｂのｇａｇタンパク質の使用 |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US9752160B2 (enExample) |
| EP (1) | EP2761011B1 (enExample) |
| JP (3) | JP6495653B2 (enExample) |
| KR (1) | KR101811736B1 (enExample) |
| CN (2) | CN107858375A (enExample) |
| AU (1) | AU2012313960B2 (enExample) |
| BR (1) | BR112014007027A2 (enExample) |
| CA (2) | CA2959867C (enExample) |
| DK (1) | DK2761011T3 (enExample) |
| ES (1) | ES2683820T3 (enExample) |
| IL (1) | IL231666B (enExample) |
| SG (1) | SG11201400987QA (enExample) |
| WO (1) | WO2013046034A2 (enExample) |
| ZA (1) | ZA201401780B (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2913854A1 (en) | 2013-06-03 | 2014-12-11 | Theravectys | Lentiviral vectors containing an mhc class i, mhc class ii, or beta-2 microglobulin upstream promoter sequence |
| WO2015063706A1 (en) * | 2013-10-31 | 2015-05-07 | Theravectys | Lentiviral vectors for expression of hiv-1 antigens |
| EP3009144A1 (en) * | 2014-10-15 | 2016-04-20 | Theravectys | Lentiviral vectors for inducing CD4+ and CD8+ immune responses in vaccination of humans |
| WO2016120489A2 (en) * | 2015-02-01 | 2016-08-04 | Theravectys | Lentiviral vectors for expression of mycobacterium tuberculosis antigens |
| US12084674B2 (en) * | 2019-10-07 | 2024-09-10 | University Of Utah Research Foundation | Methods and compositions for a HIV based delivery system |
| US20250319173A1 (en) * | 2021-03-12 | 2025-10-16 | Institut Pasteur | Lentiviral vectors targeting antigens to mhc-ii pathway and inducing protective cd8+ and cd4+ t-cell immunity in a host |
| CN114107393A (zh) | 2021-04-07 | 2022-03-01 | 上海劲威生物科技有限公司 | 一种治疗乙型肝炎的慢病毒载体、慢病毒颗粒及其制备方法和应用 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2646606B1 (fr) * | 1989-05-03 | 1994-06-17 | Inst Nat Sante Rech Med | Retrovirus hautement cytopathogenique hiv-ndk. fragment d'adn de ce retrovirus, procede de preparation d'une proteine et/ou enzyme de ce virus et leurs utilisations |
| UA68327C2 (en) * | 1995-07-04 | 2004-08-16 | Gsf Forschungszentrum Fur Unwe | A recombinant mva virus, an isolated eukaryotic cell, infected with recombinant mva virus, a method for production in vitro of polypeptides with use of said cell, a method for production in vitro of virus parts (variants), vaccine containing the recombinant mva virus, a method for immunization of animals |
| US7262049B2 (en) * | 1999-03-16 | 2007-08-28 | Dana-Farber Cancer Institute, Inc. | Pseudotyped lentiviral vectors and uses thereof |
| EP1610816B1 (en) * | 2003-03-28 | 2013-01-02 | GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | Mva virus expressing modified hiv envelope, gag, and pol genes |
| GB0318704D0 (en) * | 2003-08-08 | 2003-09-10 | Sirus Pharmaceuticals Ltd | Chimaeric vector system |
| CA2539021A1 (en) | 2003-09-15 | 2005-03-31 | Chiron Corporation | Combination approaches for generating immune responses |
| GB0702694D0 (en) * | 2007-02-12 | 2007-03-21 | Ark Therapeutics Ltd | Vectors |
| CN101353667B (zh) * | 2008-08-15 | 2011-06-08 | 中国人民解放军军事医学科学院微生物流行病研究所 | Hiv毒株耐药表型分析细胞模型及其专用假型慢病毒 |
-
2012
- 2012-09-25 WO PCT/IB2012/002363 patent/WO2013046034A2/en not_active Ceased
- 2012-09-25 ES ES12813090.3T patent/ES2683820T3/es active Active
- 2012-09-25 SG SG11201400987QA patent/SG11201400987QA/en unknown
- 2012-09-25 AU AU2012313960A patent/AU2012313960B2/en active Active
- 2012-09-25 JP JP2014531334A patent/JP6495653B2/ja active Active
- 2012-09-25 CA CA2959867A patent/CA2959867C/en active Active
- 2012-09-25 EP EP12813090.3A patent/EP2761011B1/en active Active
- 2012-09-25 DK DK12813090.3T patent/DK2761011T3/en active
- 2012-09-25 US US14/346,961 patent/US9752160B2/en active Active
- 2012-09-25 CN CN201710942647.XA patent/CN107858375A/zh active Pending
- 2012-09-25 CN CN201280046712.6A patent/CN104039968B/zh active Active
- 2012-09-25 BR BR112014007027A patent/BR112014007027A2/pt not_active Application Discontinuation
- 2012-09-25 KR KR1020147009812A patent/KR101811736B1/ko active Active
- 2012-09-25 CA CA2849652A patent/CA2849652C/en active Active
-
2014
- 2014-03-11 ZA ZA2014/01780A patent/ZA201401780B/en unknown
- 2014-03-23 IL IL231666A patent/IL231666B/en active IP Right Grant
-
2016
- 2016-09-12 JP JP2016178074A patent/JP2017018132A/ja active Pending
-
2017
- 2017-08-10 US US15/673,454 patent/US20170362607A1/en not_active Abandoned
-
2018
- 2018-07-19 JP JP2018135840A patent/JP2018183165A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010535495A5 (enExample) | ||
| JP2012509340A5 (enExample) | ||
| Kim et al. | Stability of retroviral vectors against ultracentrifugation is determined by the viral internal core and envelope proteins used for pseudotyping | |
| EP2359851A3 (en) | MVA expressing modified hiv envelope, gag, and pol genes | |
| GB2540694A (en) | CCR5 disruption of cells expressing anti-hiv chimeric antigen receptor (CAR) derived from broadly neutralizing antibodies | |
| AU2014203512B2 (en) | Recombinant virus-like particles encoded by multi-gene vector | |
| JP2014532402A5 (enExample) | ||
| JP2012520084A5 (enExample) | ||
| Ali et al. | Cross-and co-packaging of retroviral RNAs and their consequences | |
| RU2015155821A (ru) | Вакцины против малярии | |
| WO2011034953A3 (en) | Lassa virus-like particles and methods of production thereof | |
| IN2015DN02546A (enExample) | ||
| JP2014513956A5 (enExample) | ||
| JP2013507107A5 (enExample) | ||
| ES2683820T3 (es) | Uso de proteínas GAG no de subtipo B para encapsidación lentiviral | |
| Fontana et al. | Mucosal immunization with integrase-defective lentiviral vectors protects against influenza virus challenge in mice | |
| Wen et al. | The novel replication-defective vaccinia virus (Tiantan strain)–based hepatitis C virus vaccine induces robust immunity in macaques | |
| IN2015DN03070A (enExample) | ||
| JP2016530890A5 (enExample) | ||
| WO2011047031A3 (en) | Eliciting immune responses using recombinant mva viruses expressing hiv env, gag and pol anitgens | |
| RU2020125098A (ru) | Рекомбинантные вирусоподобные частицы (vlp) с использованием протеина группового антигена (gag) вируса бычьего иммунодефицита | |
| MX354571B (es) | Genomas lentivirales quimericos no integrativos como vacunas innovadoras contra el virus de la inmunodeficiencia humana tipo 1 (vih-1). | |
| WO2012159120A3 (en) | Gene therapy based strategy for treating hiv | |
| WO2021216615A1 (en) | Highly-networked coronavirus immunogen composition | |
| EP3937976A1 (en) | Highly networked immunogen composition |